Tumour necrosis factor alpha inhibitors for the treatment of adult rheumatoid arthritis

Australian Prescriber

Volumn 27, Issue 2, 2004, Pages

  McColl, Geoff ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b S Plough Infliximab Advsy Board   (Australia)

Author keywords

Adalimumab; Etanercept; Infliximab

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; CELL ADHESION MOLECULE; CHIMERIC ANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; ETANERCEPT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; METALLOPROTEINASE; METHOTREXATE; MONOCLONAL ANTIBODY; PROTEIN P75; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

BONE DESTRUCTION; CANCER; CANCER RISK; CARTILAGE DEGENERATION; CELL TRANSFORMATION; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CYTOKINE RELEASE; DEMYELINATING DISEASE; DISEASE CONTROL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG MECHANISM; ENVIRONMENTAL FACTOR; FIBROBLAST; GENETIC PREDISPOSITION; HUMAN; INFECTION; INFECTION RISK; INJECTION SITE; JOINT DEGENERATION; NONHUMAN; OPPORTUNISTIC INFECTION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PHARYNGITIS; PROTEIN INDUCTION; RASH; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIGNAL TRANSDUCTION; SINUSITIS; SKIN MANIFESTATION; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 1942424858     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2004.038     Document Type: Review

References (10)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
2. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 1999;354:1932-9. (randomised trial, sponsored trial)
3. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602. (randomised trial, sponsored trial)
4. Moreland LW, Schiff H, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999;130:478-86. (randomised trial, sponsored trial)
5. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox IR, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9. (randomised trial, sponsored trial)
6. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-93. (randomised trial, sponsored trial)
7. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
8. Sharp JT. An overview of radiographic analysis of joint damage in rheumatoid arthritis and its use in metaanalysis. J Rheumatol 2000;27:254-60.
9. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
10. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.